Biogen’s stock slides on soft guidance and a decline in sales of MS drugs
Read more at MarketWatch
Topics
-
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.CNBC - 3h -
FIS shares plunge most since 2023 on disappointing revenue, guidance miss
Shares of Fidelity National Information Services had their worst day on the market since 2023 after the company's disappointing guidance.CNBC - 2h -
Frontier’s stock slides 3% as Spirit rebuffs budget airline’s takeover offer for a third time
Frontier reiterates view that combining makes more sense than Spirit going it aloneMarketWatch - 2h -
Why Micron’s stock is leading the chip sector’s decline
Micron CFO Mark Murphy mentioned various factors that could weigh on margins for next quarter, but he also said that period should mark the low point.MarketWatch - 3h -
Lyft has ‘no obvious answers’ for its growth woes, as its stock declines
One issue for Lyft is a downturn in pricing trends, which numerous analysts keyed in on as they looked to make sense of the path forward.MarketWatch - 4h -
Shopify beats on fourth-quarter revenue, but gives mixed guidance
Shopify said the first quarter is "consistently" its lowest gross merchandise volume quarter seasonally.CNBC - 22h -
We're adding to our position in a sliding stock and booking profits in a 2025 winner
We're making a pair of trades Monday as Wall Street rallies to kick off the week.CNBC - 2d -
Canopy Growth’s drop in adult-use pot sales snuffs out cannabis-stock momentum
Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.MarketWatch - 4d -
Doximity shares pop 36% on revenue beat, rosy guidance
The company built a digital platform for medical professionals that can help them carry out telehealth appointments with patients, find referrals and more.CNBC - 4d
More from MarketWatch
-
Hot CPI reignites stagflation fears. Here’s why that would be disastrous for your 401(k).
The recently retired and the almost-retired are most at risk.MarketWatch - 4m -
‘Stagflation-lite?’ Economy may face fresh threat of slower growth and rising inflation
President Trump vows to unleash the U.S. economy, but his agenda is creating lots of uncertainty.MarketWatch - 15m -
CVS’s stock is having its best day since 1999, after more than just earnings
CVS’s stock soared toward after its quarterly profit beat expectations by the widest margin in more than four years.MarketWatch - 52m -
Trump’s tariffs and tax plans are inflationary. Voters won’t tolerate it.
Trump can no sooner repeal the law of gravity than change some macroeconomic realities.MarketWatch - 1h -
Fed is going to be even more cautious about inflation after CPI report
Federal Reserve Chair Jerome Powell said Wednesday that the Fed is “holding” while awaiting more data.MarketWatch - 1h
More in Business
-
Hopes for more Fed rate cuts dim as Powell notes hot CPI means 'we're not quite there yet'
A Fed interest rate cut won't be coming until at least September, if at all this year, following a troubling inflation report Wednesday.CNBC - 2m -
Hot CPI reignites stagflation fears. Here’s why that would be disastrous for your 401(k).
The recently retired and the almost-retired are most at risk.MarketWatch - 4m -
India's Modi to meet with Trump, Musk on Thursday as trade tensions mount
Indian Prime Minister Narendra Modi has meetings set up for Thursday with President Donald Trump and Tesla CEO Elon Musk, among other leaders.CNBC - 9m -
US inflation unexpectedly increases to 3% in January
Figure bolsters case for Federal Reserve proceeding slowly with interest rate cutsFinancial Times - 9m -
Mitch McConnell says Trump's trade war will raise prices: 'Tariffs are bad policy'
Mitch McConnell and Donald Trump have had a rocky relationship since their falling out over Trump's loss to Joe Biden in the 2020 presidential election.CNBC - 13m